Key facts
- This page summarizes Joseph Sinkule's Form 4 filing for Klotho Neurosciences, Inc. (KLTO).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 06 Mar 2026, 15:11.
Joseph Sinkule - 04 Mar 2026 Form 4 Insider Report for Klotho Neurosciences, Inc. (KLTO)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- KLTO
- Reported as of
- 04 Mar 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 06 Mar 2026, 15:11:01 UTC
- Prior SEC filing
- 29 Sep 2025
- Source filing
- View source filing
- Reporting owner signature
- Joseph Sinkule
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Joseph Sinkule filed Form 4 for Klotho Neurosciences, Inc. (KLTO) on 06 Mar 2026.
Change
- Previous filing in this sequence was filed on 29 Sep 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001524409
Primary reporting owner
SINKULE JOSEPH
- Relationship
- Chief Executive Officer, Director
- Address
- 1300 SOUTH BOULEVARD SUITE D, CHARLOTTE
- Signature
- Joseph Sinkule
- Signature date
- 06 Mar 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KLTO
transaction
Common Stock
Award
- Transaction value
- Shares
- +2,500,000
- Change %
- +65%
- Price
- Shares after
- 6,346,700
- Date
- 04 Mar 2026
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The Reporting person received the shares as a grant under the company's Equity Incentive Plan.